secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2025-09-22T23:59:59+00:00
Accession:  0001534120-25-000005
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics appoints Kevin Lind to Board effective Oct 1; Dr. Almenoff resigns
--------------------------------------------------------------------------------

- Kevin Lind appointed to Board effective Oct 1, 2025; will serve on Audit Committee and receive option for 40,200 shares vesting over 3 years.
- Lind previously led Longboard Pharmaceuticals to $2.6B acquisition by Lundbeck in 2024; was EVP/CFO at Arena Pharmaceuticals.
- June Almenoff resigns as director effective Oct 1; her equity awards modified to vest fully and options extended to Sept 30, 2026.
- Company advancing Phase 2 LOTUS trial of AVTX-009 in hidradenitis suppurativa; topline data expected mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000153412025000005/0001534120-25-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000153412025000005/avtx-20250916.htm
  HTML page:      https://secwatch.observer/filing/0001534120-25-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer